MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing RightsZacks Investment Research • 07/17/25
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)GlobeNewsWire • 07/16/25
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver FibrosisGlobeNewsWire • 06/20/25
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care ConferenceGlobeNewsWire • 06/02/25
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH CirrhosisGlobeNewsWire • 05/10/25
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/01/25
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL CongressGlobeNewsWire • 04/29/25
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025GlobeNewsWire • 04/18/25
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.GlobeNewsWire • 04/16/25
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/28/25
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)Seeking Alpha • 02/28/25
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpZacks Investment Research • 02/26/25
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver CirrhosisBenzinga • 02/26/25
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger OutlookSeeking Alpha • 02/26/25
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH CirrhosisGlobeNewsWire • 02/26/25